Health Care [ 4/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States.
The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults.
It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder.
In addition, the company develops lenrispodun (ITI-214) in Phase 2 clinical trial for the treatment of Parkinson's disease; ITI-1284-ODT-SL in Phase 2 trial for the treatment of generalized anxiety disorder, and psychosis and agitation in patients with Alzheimer's disease; ITI-1020 in Phase 1 trial for cancer immunotherapy; and ITI-1549 in preclinical studies for mood and anxiety disorders.
It distributes its products through third-party wholesale drug distributors.
Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in Bedminster, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | -0.16 Increased by +46.67% | -0.11 Decreased by -44.27% |
| Oct 30, 24 | -0.25 Increased by 0.00% | -0.20 Decreased by -25.00% |
| Aug 7, 24 | -0.16 Increased by +64.44% | -0.19 Increased by +15.79% |
| May 7, 24 | -0.16 Increased by +65.22% | -0.32 Increased by +50.00% |
| Feb 22, 24 | -0.30 Increased by +33.33% | -0.44 Increased by +31.82% |
| Nov 2, 23 | -0.25 Increased by +56.14% | -0.57 Increased by +56.14% |
| Aug 3, 23 | -0.45 Increased by +51.09% | -0.59 Increased by +23.73% |
| May 4, 23 | -0.46 Increased by +41.03% | -0.61 Increased by +24.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 199.22 M Increased by +51.49% | -16.89 M Increased by +40.92% | Decreased by -8.48% Increased by +61.00% |
| Sep 30, 24 | 175.16 M Increased by +39.23% | -26.32 M Decreased by -8.52% | Decreased by -15.03% Increased by +22.06% |
| Jun 30, 24 | 161.39 M Increased by +46.55% | -16.22 M Increased by +62.09% | Decreased by -10.05% Increased by +74.13% |
| Mar 31, 24 | 144.87 M Increased by +52.92% | -15.25 M Increased by +65.39% | Decreased by -10.52% Increased by +77.37% |
| Dec 31, 23 | 131.51 M Increased by +50.41% | -28.58 M Increased by +23.29% | Decreased by -21.73% Increased by +49.00% |
| Sep 30, 23 | 125.81 M Increased by +75.05% | -24.26 M Increased by +54.66% | Decreased by -19.28% Increased by +74.10% |
| Jun 30, 23 | 110.13 M Increased by +99.96% | -42.78 M Increased by +49.04% | Decreased by -38.85% Increased by +74.52% |
| Mar 31, 23 | 94.73 M Increased by +172.57% | -44.05 M Increased by +38.92% | Decreased by -46.50% Increased by +77.59% |